Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth
Q4 2024 Management View CEO Fabrice Chouraqui highlighted a strong performance in 2024 with revenue growth of 21% to $297 million, exceeding guidance. He emphasized RUCONEST's growth of 11% to $252 ...
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...
The Pharma Letter10h
Pharming reports revenue growth and strategic expansion in 2024
Dutch biopharma company Pharming (Euronext Amsterdam: PHARM) has reported a 21% increase in revenue for 2024, reaching $297 ...
Pharming Group to participate in March investor conference
Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will ...
ETF Daily News3d
Pharming Group (PHAR) Expected to Announce Earnings on Thursday
Pharming Group has a 52-week low of $6.65 and a 52-week high of $11.94. The stock has a market capitalization of $541.53 million, a P/E ratio of -30.62 and a beta of -0.10. Get Pharming Group alerts: ...
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended ...
Pharming Group (NASDAQ:PHAR) Shares Gap Up – What’s Next?
Pharming Group (NASDAQ:PHAR – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $8.54, but opened at $9.06. Pharming Group shares last traded at $9.15, ...
Business Insider9d
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of ...
The National Law Review22d
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
Leiden, the Netherlands, February 20, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer ...
Morningstar14d
Pharming Group to participate in March investor conference
For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [email protected] or ...
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to ...
The Bakersfield Californian15d
Pharming Group to participate in March investor conference
Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following ...